States become infected with antibiotic-resistant bacteria, of which, approximately 23000 die as a direct result of these infections. Phage therapy, or the treatment of bacterial infection by specific, antagonistic viruses, provides one alternative to traditional antibiotics. Bacteriophages, or phages, are bacteriaspecific viruses that possess biological traits that allow for not only the removal of bacterial infection, but also the evasion of bacterial resistance, which renders antibiotics ineffective. Previous research has shown the addition of iron-doped apatite nanoparticles (IDANPs) to bacteria prior to phage exposure results in increased bacterial plaques in vitro. Coupled with the biocompatible nature of apatite, these results provide promise for future use of IDANPs as adjuvants to phage therapy along with anti-bacterial applications yet to be explored. Although IDANP enhancement of phage infection has been replicated many times in gram-positive and gram-negative prokaryotic hosts as well as with the utilization of both RNA and DNA viruses, the specific mechanisms involved remain elusive. To further understand increased phage infections in a prokaryotic system, and to evaluate the safety of IDANPs as a treatment used in a eukaryotic system, we have replicated plaque assay experiments in an algal system using Chlorella variabilis NC64A and its virus, Paramecium bursaria chlorella virus 1 (PBCV-1). Statistical modeling was used to evaluate alteration in numbers of plaques observed after viral introduction in IDANP-exposed versus non- Manuscript received June 29, 2016; revised September 12, 2016 and October 11, 2016; accepted October 11, 2016 
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I. INTRODUCTION

E
RNEST Hanbury Hankin, a British bacteriologist, was the first to demonstrate a biological specimen which kills bacteria. In 1896, Hankin discovered a filterable, biological principle from the waters of the Ganga and Yamuna Rivers in India that could eliminate cholera-inducing bacteria and pass through millipore filters that were known to trap bacterial cells. He published his work in the Annals of the Pasteur Institute [1] . Although some controversy exists as to whether what Hankin discovered was truly the same specimen [2] , his discovery was followed approximately 20 years later by the work of Fredrick W. Twort of Great Britain who also described a filterable, clear agent that could break down bacteria [3] . Two years later in France, Félix d'Hérelle, a Canadian-born researcher, independently discovered a similar phenomenon while studying patients with bacillary dysentery [4] .
These biological specimens that rid the human body of bacterial infection were later named by d'Herelle as bacteriophage (phage). The ability of the phage to kill bacteria is dependent upon successful phage adherence to the cell surface and injection of viral genetic material [5] . Injected phage genetic material then initiates the bacterial cell's reproductive processes to produce phage inside bacteria cell protoplasm. Once phage populate a majority of the bacterial volume and a sufficient quantity of phage lysin protein is present, the bacterial cell wall and membrane lyse and newly synthesized phage are released, that in turn, infect and kill more bacteria. In in vitro plaque assay experiments, lysis is arrested at a single infection through the addition of top agar as a solidifying agent. In plaque assay experiments, lysis and destruction of a bacterial cell results in the formation of a vacant, circular area formed in a cell lawn grown on agar plates. These vacancies, better known as "plaques," contain billions of newly released phage and were first described by d'Herelle. The number of viral particles released is highly dependent on phage and bacterial health as well as many other environmental factors [6] . Armed with the understanding that phages kill bacteria, d'Herelle was also credited with being the first to utilize phage to treat human bacterial diseases such as bubonic plague and cholera [7] . More recently, phage have been shown to arrest diabetic foot infections and speed up the healing process [8] , and to reduce bacterial colony formation in diabetic cutaneous wounds [9] . Phage have been used to remove bacteria from catheters and biofilms [10] and to supplement antibiotics when used to prevent immunological attack in a patient with an artificial implant [11] . Such examples demonstrate the importance, potential, and ultimately the motivation to improve and enhance phage therapeutics.
In a similar manner to that of phage and bacterial cells, the virus Paramecium bursaria chlorella Virus 1 (PBCV-1) attaches to its eukaryotic Chlorella variabilis NC64A host [12] - [14] and viral DNA is transferred from virus to host. Once inside C. variabilis, PBCV-1 viral DNA commandeers host replication, transcription, and translation machinery [15] . As in phage infection of bacteria, PBCV-1 particles are assembled within the C. variabilis host until conditions allow viral particles to be released into the surrounding environment. In addition to this similarity, in vitro plaque assay experiments have revealed C. variabilis cell destruction and release of PBCV-1 results in plaque formation [16] . (See Fig. 1 ). Similar host-virus interactions and utilization of identical measures for quantification of cell death, make comparison of bacteria/phage and C. variabilis/PBCV-1 systems an excellent model for statistical comparison of specific influences examined across prokaryotic versus eukaryotic host/virus systems.
Chlorella variabilis NC64A [17] . is a unicellular, green alga that exists in aqueous environments in sizes that range from 2 to 10 μm [18] . C. variabilis is a member of the true Chlorella genus, characterized by glucosamine as a major component of their rigid cell walls [19] , [20] . Algae originally classified in the genus Chlorella are among the most widely distributed and frequently encountered algae in freshwaters [21] , existing in aqueous environments as well as on land. In nature, C. variabilis is a hereditary photosynthetic endosymbiont of the unicellular protozoan Paramecium bursaria [22] , but it can be grown and studied in the laboratory as axenic culture. While inside P. bursaria, C. variabilis is immune to viral attack by PBCV-1 despite the virus existing in titers seen as high as 10 5 PFU per ml [23] - [24] . PBCV-1 was first isolated in 1982 and its life cycle was characterized in 1983 by Van Etten et al. [25] , [26] . Additional literature which describes the genetics, structure, and evolution of C. variabilis and PBCV-1 can be found at references [27] - [31] . Although little is known about the effect of chloroviruses on freshwater ecology [32] , the ability of these viruses to lyse host cells within 6 to 16 hours in the laboratory with burst sizes exceeding 100 PFU per cell [12] , [33] , supports the hypothesis that PBCV-1 has the potential to alter microbial communities and act as a driving force for microbial evolution [34] , [35] .
The following investigations involved plaque assay experiments and subsequent statistical analysis to evaluate the effect of iron-doped apatite nanoparticles (IDANPs) on PBCV-1 infection of C. variabilis. Previous research has demonstrated that upon addition of specifically synthesized IDANPs to various bacterial strains prior to viral introduction and plating, bacterial plaques increased to more than two times that of bacteria-only controls [36] . These results have prompted research into IDANPs as an adjuvant to enhance phage therapeutics. Nanoparticles (NPs) used in our experiments are composed of calcium, phosphate, and hydroxyl ions and resemble hydroxyapatite (HA). HA is a mineral known to be analogous to the inorganic constituent of mammalian bone and teeth [38] . The biomimetic properties of HA allow potential for IDANPs to serve as biocompatible adjuvants capable of entering a physiological system without significant immune system rejection. Previous investigations in our laboratories have accomplished the synthesis of citrate functionalized and dispersed IDANPs [36] . During the reaction, it is thought that citrate ions complex with Ca 2+ , and mediate the reaction leading to the formation of apatite nanoparticles (ANPs). The carboxylates of citrate, which at physiological pH are deprotonated, give rise to Coulombic repulsion in adjacent NPs. This repulsion causes dispersion of individual ANPs and colloid formation.
Phage therapy provides an alternative to traditional antibiotics, to which, bacteria are becoming increasingly resistant. The impending need for new bacteria-eliminating treatments has been emphasized by the President's Council of Advisors on Science and Technology for 2016 [37] . The need for research focused on alternative antibiotics, coupled with the biocompatible nature of apatite, make IDANP-mediated bacterial death of great interest for antibacterial applications. Although many experimental repetitions have shown IDANPs enhance bacterial cell death by phage [37] , IDANPs appear to have very little effect on bacterial growth or colony formation. The observation that NPs may not be directly harmful to cells but instead facilitate cell death by virus, corroborates the importance of investigating not only the direct effect IDANPs have on eukaryotic host cells, but also the interaction IDANPs have on microbes or other materials in the extracellular environment. The following article provides our first investigation into the effect IDANPs have on eukaryotic host cell viruses using C. variabilis and its virus, PBCV-1. Results of these studies are statistically compared to that of IDANPs on a S. aureus /phage system.
II. METHODS
A. Synthesis of Iron-Doped Apatite Nanoparticles
Synthesis of IDANPs has been described by J. M. Andriolo et al. [36] . During synthesis, it was assumed that iron replaces calcium in the apatite unit cell to 30% iron in the ratio of total iron plus calcium. Citrate was used as a capping agent to arrest nanoparticles at the nanoscale (see Fig. 2 ). The reaction formula used is as follows:
During synthesis of 30% IDANPs with 1X citrate, a 500 mL flask held at temperature was filled with 200 mL deionized water and stirred as the following reagents were added in the order listed:
• 0.260 g Calcium Hydroxide (Ca(OH) 2 )
• 0.243 g Iron Chloride (FeCl 3 )
• 0.263 g Citric Acid Anhydrous (C 6 H 7 O 7 )
• 0.408 g monopotassium phosphate (KH 2 PO 4 ) that was pre-dissolved in 50 mL deionized water is added dropwise over a period of 1 minute. The final solution was measured at a pH of approximately 4.5 and was subsequently brought up to a pH of 7.5 using 1 M NaOH and allowed to stir on hot plate for seven days before being sterilized in an autoclave for 40 min. Plaque assay results have shown IDANP effect on phage infection of bacteria is not affected by autoclaving (data not shown). IDANP concentration resulting from this synthesis procedure was estimated to be 1.4 mg/mL. Concentration was determined by isolating formed particles via ultracentrifugation and washing. Washed IDANPs were then lyophilized and weighed.
B. Sample Preparation for Scanning Electron Microscopy
Preparation of NP samples for examination under scanning electron microscopy (SEM) has been described by J. M. Andriolo et al. [36] . The SEM used was a Hitachi S-4500.
Biological sample preparation began by mimicking conditions used for in vitro plaque assay experiments [36] (Methods Sections C and E) up to the point of plating. Instead of plating, 100 μL of cells (either pre-exposed to NPs or cell media only) were placed on an aluminum stub and immediately freezedried at -80 • C. Samples were then dehydrated slowly using a 10% ethanol gradient from 10%-100%. During dehydration, samples were undisturbed for 10 min at each ethanol concentration, the last (100%) concentration being replicated twice. A final step involved hexamethyldisilazane (HMDS) chemical drying procedure where 100% HMDS was added to the aluminum stub, and the final sample sat in ambient conditions until dry. Gold coating was employed prior to examination under electron microscopy.
C. Cultivation and Exposure of Staphylococcus aureus (ATCC33742) to IDANPs, Infection by JB Bacteriophage, and Subsequent Plaque Assay
Conditions for S. aureus exposure to IDANPs, infection by JB phage, and subsequent plaque assay has been described by J. M. Andriolo et al. [36] .
S. aureus cells were initially grown in overnight culture of 3 mL tryptic soy broth that was supplemented with 1 mM calcium chloride and 25 mL/L of 20% dextrose (20 g dextrose/100 mL sterile deionized water) solution (TSB ++ ). On the day of the experiment, S. aureus was placed in a 1:100 dilution of TSB ++ and grown for 3 hours in a shaker held at 37 • C and 225 rpm. At 3 hours, cells were exposed to either NPs or TSB ++ treatments in individual test tubes at a ratio of 1:1 (250 μL:250 μL) and placed back in the shaker to grow for an additional hour prior to infection by JB phage. At 4 hours, JB phage was added to test tubes and allowed to adhere and infect for 10 min. After viral adherence and infection, tryptic soy top agar (TSTA) that was pre-mixed 1:1 with TSB ++ was added to individual tubes before being poured onto plates for plaque assay. Tryptic soy agar (TSA) plates (40 g/L) supplemented with 1 mM calcium chloride and 25 mL/L 20% dextrose solution were used for plaque assay. Tryptic soy top agar (TSTA) was prepared by adding 7 g/L agar to tryptic soy broth (TSB).
D. Cultivation of Chlorella variabilis NC64A
C. variabilis stock was obtained from the University of Nebraska Lincoln and stored at 4 • C. Stock C. variabilis cells were added at 1 mL stock per 250 mL modified Bold's basal media (MBBM). MBBM has been described by Van Etten et al. in 1983 [25]. C. variabilis was grown in a shaker at 26 • C and 225 rpm under soft white 40 W light. Growth of cells was monitored via direct cell counting with a hemocytometer. Cells were grown to approximately 5 × 10 6 cells/mL, centrifuged, and re-suspended to a concentration of approximately 4 × 10 8 cells/mL in MBBM prior to exposure to IDANPs and virus.
E. Exposure of Chlorella Variabilis NC64A to IDANPs, Infection by PBCV-1, and Subsequent Plaque Assay
Plaque assay protocols were adapted from Van Etten labs at the University of Nebraska, Lincoln [15] . Modifications made were mainly to accommodate differences in maximum growth and growth time variations that presumably occurred due to differences in climate and/or growth environment.
Prior to experiments, glass petri dishes were prepared with 1.5% agar in Modified Bold's Basal Media (MBBM). Top agar was prepared at 0.75%.
On the day of plaque assay, C. variabilis cells were exposed to NPs or MBBM in a 1:1 dilution for time points from 0 to 140 min in a shaker held at 26 • C and 225 rpm prior to infection by PBCV-1 and plating for plaque assay. Just before the addition of PBCV-1 to treated C. variabilis cells, glass test tubes were filled with 2.5 mL top agar and tubes were kept in a hot water bath held at 45 • C-50 • C. C. variabilis cells concentrated to approximately 4 × 10 8 cells/mL were added at a volume of 0.15 mL to top agar and immediately followed by 0.1 mL PBCV-1 diluted to approximately 5 × 10 2 PFU/mL. Negative controls were prepared in the same manner as all other plates with the exception that in place of virus, 0.1 mL MBBM was added immediately following cells.
Test tubes containing treated cells and virus were quickly rolled between two palms before being poured onto agar plates. Plates were then rocked at room temperature to coat the agar surface. After solidification, plates were incubated facedown at 26 • C under 40 W soft white light for 2 to 4 days or until clear plaques formed on all plates. Data were recorded in the form of plaque counts.
F. Statistical Analysis
Nine treatments were studied in both systems individually in a preliminary experiment and analyzed to determine the influence of IDANPs on viral infection of host cells. The treatments were chosen to represent both those that have previously been shown to cause plaque increases as well as those that were not linked to plaque increases in previously studied bacterial systems. The nine treatments studied are included in Table I . Those ANPs which caused the greatest difference in plaques as determined by the initial statistical analysis were replicated 8-10 more times in 1-2 experiments and statistically analyzed.
Negative control plates which included no added virus were also studied but revealed no plaques, thereby indicating PBCV-1 or JB phage as the source of plaques seen in the rest of our treated or control plates.
For each experiment, a randomized design was used to assign NP or cell media (TSB ++ or MBBM) treatments to the cell culture tubes prior to infection by virus (JB phage or PBCV-1). A randomized design was also used to assign treated, infected cells to agar plates for plaque assay. The observed value for the jth replicate (plated plaque assay replicate) of the ith treatment (NP or cell media treatment used during pre-exposure), Y i j, is a count of plaques, and therefore, a Poisson regression model was used to model the mean count, E(Y i j). The Poisson regression model is
where α i is the ith treatment effect. Statistical package R was used to fit the data to the model as a generalized linear model.
The goodness of fit between the data and the model was assessed using the residual deviance goodness of fit test. Provided there was no evidence of a significant lack of fit, the null deviance model utility test was used to test for significant differences in the treatment effects. For a significant model utility test, Tukey's pairwise multiple comparison procedure was used to identify significant differences between the treatment effects. Finally, when two treatment effects were significantly different, a 95% confidence interval for the difference of the treatment effects was computed and then back-transformed into a confidence interval for the ratio of their means.
III. RESULTS
A. Scanning Electron Micrographs of Host Cells after Exposure to 30% Iron-Doped Apatite Nanoparticles Synthesized at 25 • C and Functionalized With Citrate
Previous investigations in our labs exposed S. aureus cells to NPs made under the following various conditions: (1) varying synthesis temperature to 25 • C, 45 • C, and 65 • C, (2) varying iron doping to 0%, 20%, 30%, and 40%, or (3) varying the amount of citrate from none, to the standard (1X) amount of citrate, to double (2X) the amount of citrate used in standard synthesis protocols. SEMs revealed that altered synthesis temperature regulates NP agglomeration properties, which decrease with increased synthesis temperature [36] . SEM micrographs also show NP morphology is altered from amorphous to spherical with increased synthesis temperature [36] . It has been proposed that varied grain sizes and alteration of exposed absorptive surface area contributes to potential applications of NPs [39] . Citrate functionalization used during synthesis also influenced NP shape through dispersion and colloid formation, thereby arresting NPs at specific sizes (see Fig. 2 ), which were shown to decrease when the amount of citrate used was doubled. Because alteration of synthesis parameters changed NP morphology, and because NPs exhibit synthesis-dependent influence on viral infection in prokaryotic systems, it is assumed agglomeration, shape, and composition of NPs used during experiments are essential to the observed increase in plaques.
SEM micrographs were collected to reveal interactions between IDANPs and host cells in the C. variabilis and S. aureus systems. Results show similar surface interactions and clumping of IDANPs on both host cell surfaces despite IDANPs having different influences on resultant plaques in plaque assay experiments (See Fig. 3) .
B. Statistical Evaluation of PBCV-1 Infection of IDANP-Exposed Chlorella Variabilis NC64A
In the preliminary experiment, C. variabilis cells were exposed to NPs synthesized under various conditions prior to the addition of PBCV-1. Results from this initial experiment indicated no statistically significant changes in plaque counts. To confirm this result, specific NPs which mediated the greatest difference in viral infections were replicated 10 times each in two replicate experiments. Results from these experiments were standardized by the average control value per individual experiment (see Fig. 4 ).
The first replicate experiment with C. variabilis and PBCV-1 included NP treatments which facilitated the greatest difference in resultant plaques (25_30_1X and 65_30_1X) in the initial experiment. Replicates were infected and plated in a completely randomized design. The fitted model appears to show no significant lack of fit (p =0.0943), and the model utility test is not significant (p =0.0860). Thus, there are no significant differences in the treatment effects for the first replicated C. variabilis /PBCV-1 experiment. A second replicate experiment was also performed, again, with completely randomized design and identical NP treatments replicated 10 times each. The fitted model appears to show no significant lack of fit (p =0.2390), and the model utility test is not significant (p =0.2758). Thus, there are also no significant differences in the treatment effects for the second replicate C. variabilis/PBCV-1 experiment. Further experiments confirm no increase in plaques as C. variabilis cells exposed to NPs over various time points up to 140 min also revealed no increased plaques. For comparison, Fig. 5 displays plated plaque assays for C. variabilis cells which were pre-exposed to either MBBM or 25_30_1X NPs prior to infection by PBCV-1. Exposure time to 25_30_1X NPs or MBBM in both cases Plaque count data standardized by the control value in final C. variabilis experiment. Initial results showed the greatest difference in viral infection imposed when C. variabilis cells were pre-exposed to IDANPs synthesized at 25 • C or 65 • C with 30% iron and 1X citrate before the addition of PBCV-1. In two replicate experiments, plaques from ten replicate plates were counted. Results from these experiments were standardized and revealed no statistically significant increase in plaques when C. variabilis cells were exposed to IDANPs prior to the introduction of PBCV-1.
was one hour. Statistical evaluation of all plaque counts reveal non-significant differences in plaque counts between cells preexposed to MBBM or 25_30_1X NPs.
C. Statistical Evaluation of JB Bacteriophage Infection of IDANP-Exposed Staphylococcus aureus (ATCC 33742)
Preliminary S. aureus /JB phage experiment utilized NPs identical to those used in the initial experiments involving C. variabilis and PBCV-1. As stated above, NPs synthesized under varying conditions have revealed altered degrees of effect on the enhancement of viral infection in prokaryotic systems [36] . These results were confirmed by this study, which showed the most effective NPs were 25_30_1X or 45_30_1X (see Fig. 6 A) .
During the initial experiment, treatments were run in a completely randomized design. The fitted model appears to show no significant lack of fit (p =0.9854), and the model utility test is significant (p =0.0125). Thus, at least one of the treatment effects is significantly different from 0. Using Tukey's pairwise multiple comparison procedure, several NP treatments demonstrated significant increases in plaques as compared to controls: 1) 25_0_1X, 2) 25_30_1X, 3) 45_30_1X, 4) 45_30_2X, and 5) 65_30_1X (refer to Table I for NP synthesis parameters of NP types). Based on the model, percent increase was inferred, as shown in Table II. Based on initial results, NPs shown to increase plaques to the greatest extent were used and replicated 8 times each in a single replicate experiment (see Fig. 6 B) . IDANPs used were: 1) 25_0_1X, 2) 25_30_1X, 3) 45_30_1X, and 4) 45_30_2X. Cells exposed to these 4 treatments were again tested in a completely randomized design. The fitted model appears to show no significant lack of fit and the model utility test is significant (p <0.001). Thus, at least one of the treatment effects was significantly different from 0. Using Tukey's pairwise multiple comparison procedure, NP treatments demonstrated significant increases in plaques as compared to controls when 25_30_1X or 45_30_1X IDANPs were used. Results also show Photographic images of final plaque assays from C. variabilis /PBCV-1 experiments. A Control plaque assay with C. variabilis cells which were pre-exposed for one hour to MBBM prior to infection by PBCV-1. Enumerated plaques were 533. B Experimental plaque assay with C. variabilis cells which were pre-exposed for one hour to 25_30_1X NPs prior to infection by PBCV-1. Enumerated plaques were 500. 25_30_1X NPs were significantly more effective at increasing plaques than 25_0_1X or 45_30_2X NPs, and 45_30_1X NPs to be significantly more effective than 25_30_1X or 45_30_2X NPs. Significant differences were not observed between plaque counts of S. aureus /JB phage systems when cells were exposed to either 25_30_1X or 45_30_1X prior to phage introduction. Based on the model, percent increase as compared to controls was inferred, as shown in Table III (refer  to Table I for synthesis parameters of NP types). . Plaque count data from initial and repeat plaque assay experiments with S. aureus /JB phage. A Initial experiment which utilized NPs of varying composition, shape, and clumping properties exposed to S. aureus cells prior to infection by JB phage. Results show the greatest influence over viral infection when S. aureus was pre-exposed to IDANPs synthesized at 25 • or 45 • C with 30% iron doping and 1X citrate. B Plaque count data from repeated experiment, in which NPs shown to cause the greatest increases in viral infections were used. Results show all NPs used increase viral infections to a statistically significant amount. The greatest increase was observed to be 37.8% observed when S. aureus cells were exposed to IDANPs synthesized at 25 • C with 30% iron and 1X citrate prior to the introduction of JB phage. IV. CONCLUSIONS Apatite nanoparticles doped with iron (IDANPs) have been used to cause significant increases in phage-mediated bacterial death. Coupled with the biocompatible nature of apatite, She is currently a graduate researcher at Montana Tech, Butte, where her research focuses on the design of polymer drug delivery systems using electrospinning fabrication methods. Her interests also include electrospinning for fabrication of micro and nano scale devices for energy harvesting and sensors.
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